Oral etoposide in elderly patients with advanced non small cell lung cancer: A clinical and pharmacological study

Journal of Chemotherapy

Volumn 18, Issue 2, 2006, Pages 188-191

  Sorio, Roberto ^a   Toffoli, G ^a   Crivellari, D ^a   Bearz, A ^a   Corona, G ^a   Colussi, A M ^a   Libra, M ^a   Talamini, R ^a   Veronesi, A ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Elderly; Etoposide; Non small cell lung cancer; Pharmacokinetics

Indexed keywords

CISPLATIN; ETOPOSIDE; NAVELBINE; PACLITAXEL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG MONITORING; DRUG TOLERANCE; FEASIBILITY STUDY; FEMALE; GERIATRIC ASSESSMENT; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; PHASE 2 CLINICAL TRIAL; TREATMENT DURATION;

EID: 33646848437     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2006.18.2.188     Document Type: Article

References (16)

1. DeMario MD, Ratain MJ. Oral chemotherapy: rationale and future directions. J Clin Oncol 1998; 16 (7): 2557-2567.
2. Skirvin JA, Lichtman SM. Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer. Drugs Aging 2002; 19 (1): 25-42.
3. Comis RL, Friedland DM, Good BC. The role of oral etoposide in non-small cell lung cancer. Drugs 1999; 58 (suppl 3): 21-30.
4. Simon R. Optimal two-stages for phase II clinical trials. Control CHn Trials 1989; 10 (1): 1-10.
5. Gentili D, Zucchetti M, Torri V, et al. A limited sampling model for the pharmacokinetics of etoposide given orally. Cancer Chemother Pharmacol 1993; 32 (6): 482-486.
6. Robieux I, Aita P, Sorio R, Toffoli G, Boiocchi M. Determination of unbound etoposide concentration in ultrafiltered plasma by high-performance liquid chromatography with fluorimetric detection. J Chromatogr B Biomed Appl 1996; 686 (1): 35-41.
7. Toffoli G, Corona G, Sorio R, et al. Population pharmacokinetics and pharmacodynamics of oral etoposide. Br J Clin Pharmacol 2001; 52 (5): 511-519.
8. nd ed. Blackwell Sc. Publ. (Oxford). 1987: 129-132.
9. Repetto L, Fratino L, Audisio RA et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 2002; 20 (2): 494-502.
10. Zagonel V, Pinto A, Serraino D et al. Lung cancer in the elderly. Cancer Treat Rev 1994; 20: 315-329.
11. Gridelli C, Maione P, Barletta E. Individualized chemotherapy for elderly patients with non small cell lung cancer. Curr Opin Oncol 2002; 14 (2): 199-203.
12. Gridelli C, Shepherd FA. Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidence. Chest 2005; 128 (2): 947-957.
13. Carney DN. The pharmacology of intravenous and oral etoposide. Cancer 1991; 67 (1): 299-302.
14. Joel SP, Shah R, Clark PI, Slevin ML. Predicting etoposide toxicity: relationship to organ function and protein binding. J Clin Oncol 1996; 14 (1): 257-267.
15. Balducci L, Yates J. General guidelines for the management of older patients with cancer. Oncology (Huntington) 2000; 14 (11A): 221-227.
16. Huisman C, Smit EF, Giaccone G, Postmus PE. Second-line chemotherapy in relapsing or refractory nonsmall-cell lung cancer: a review. J Clin Oncol 2000; 18 (21): 3722-3730.